No treatment arm of interest (12 studies)
Lebwohl 2003
Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–13.
Gordon 2003
Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073–80.
ACD2058g
ACD2058g. Phase III, randomised double blind placebo-controlled study evaluating 12 weeks of therapy with XOMA1 efalizumab administered subcutaneously (SC), followed by either continued treatment for an additional 12 weeks or re-treatment for 12 weeks following relapse. In Clinical and Cost-effectiveness of Efalizumab (Raptiva) for Moderate to Severe Psoriasis. Industry submission. Feltham: Serono Ltd; 2004.
ACD2600g
ACD2600g. Phase IIIb, randomised, double-blind, parallel group, placebocontrolled, multicentre study evaluating 12 weeks therapy with subcutaneously administered Genentech efalizumab in adults with moderate to severe psoriasis who are candidates for systemic therapy. In Clinical and Cost-effectiveness of Efalizumab (Raptiva) for Moderate to Severe Psoriasis. Industry submission. Feltham: Serono Ltd; 2004.
IMP24011
IMP24011. Phase III, randomised, double blind, placebo-controlled, multicentre study evaluating 12 weeks subcutaneous therapy with Genentech efalizumab in patients with moderate to severe psoriasis who are candidates for systemic therapy. In Clinical and Cost-effectiveness of Efalizumab (Raptiva) for Moderate to Severe Psoriasis. Industry submission. Feltham: Serono Ltd; 2004.
Rich 2013
Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, Phase II regimen-finding study. Br J Dermatol 2013;168:402–11.
Papp 2013
Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo controlled Phase II dose-ranging study. Br J Dermatol 2013;168:412–21.
SCULPTURE 2013
Novartis. Study Comparing secukinumab Use in Long-term Psoriasis maintenance therapy: fixed regimens versus re-Treatment Upon start of Relapse (SCULPTURE). 2013.
Mroweitz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015;73:27–36.e1.
ERASURE 2014
Rich P, Karpov A, Papavassilis C, Marmur E, Klingo K, et al. Secukinumab efficacy stratified by body weight: a subanalysis from the ERASURE study. J Am Acad Dermatol 2014;70:AB186.
Papp K, Karpov A, Papavassilis C, Melendez E, Nakagawa H, et al. Secukinumab efficacy in relationship with response to previous biologic psoriasis therapy: a subanalysis from the ERASURE Study. J Am Acad Dermatol 2014;70:AB186.
Lebwohl M, Vender R, Menter A, Karpov A, Papavassilis C. ERASURE: Secukinumab Shows Sustained Efficacy in Subjects Regardless of Previous Biologic Exposure. European Association of Dermatology and Venereology (EADV) Congress, Amsterdam, the Netherlands, October 2014.
Gottlieb A, Gnanasakthy A, Strober B, Zhang JJ, Tran MH. Secukinumab’s time to posriasis response on patient-reported symptoms (ERASURE study). J Am Acad Dermatol 2014;70:AB189.
Novartis. Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis (ERASURE). 2013.
FEATURE 2014
Blauvelt A, Gottlieb A, Prinz J, Pathan R, Cooper S. Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE). J Am Acad Dermatol 2014;70:AB185.
Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab adminstration by pre-filled syringe: efficacy, safety and usability results from a randomised controlled trial in psoriasis (FEATURE). Br J Dermatol 2015;172:484–93.
Novartis. First study of secukinumab in pre-filled syringes in subjects with chronic plaque-type psoriasis: response at 12 weeks (FEATURE). 2014. URL: https://clinicaltrials.gov/ct2/show/NCT01555125 (accessed 15 September 2017).
JUNCTURE 2015
Blauvelt A, Gottlieb A, Prinz J, Pathan R, Cooper S. Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE). J Am Acad Dermatol 2014;70(Suppl. 1):AB185.
Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2015;29:1082–90.
Novartis. Judging the Efficacy of SecUkinumab in Patients with Psoriasis using Autoinjector: a Clinical Trial EvalUating Treatment Results (JUNCTURE). 2014. URL: https://clinicaltrials.gov/ct2/show/NCT01636687 (accessed 15 September 2017).
Rivas E, Griffiths C, Rich P, Gong Y, Papavassilis C. FIXTURE: Secukinumab Shows Sustained Efficacy in Subjects Regardless of Previous Biologic Exposure. European Association of Dermatology and Venereology (EADV) Congress, Amsterdam, the Netherlands, October 2014.
FIXTURE 2014
Novartis. FIXTURE (Full year Investigative eXamination of secukinumab vs. eTanercept Using 2 dosing Regimens to determine Efficacy in psoriasis). 2013.
Reich K, et al., editors. Sustainability of response with secukinumab to 52 weeks in moderate-to-severe plaque psoriasis: data from the full year investigative examination of secukinumab vs. etanercept using 2 dosing regimens to determine efficacy in psoriasis (FIXTURE) study. 2014.
Treatment arm of interest but not the recommended dose (four studies)
Tyring 2007
Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719–26.
Bagel 2012
Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 2012;67:86–92.
Tyring S, Bagel J, Lynde C, Klekotka P, Thompson EH, Gandra SR, et al. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept. J Eur Acad Dermatol Venereol 2013;27:125–8.
Gottlieb 2011
Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165:652–60.
Strober 2011
Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a Phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165:661–8.
